Top ▲

Bromodomain kinase (BRDK) family

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

GtoImmuPdb view: ON   


« Hide More detailed introduction

Bromodomain (BRD)-containing kinases initiate acetylation-dependent assembly of transcriptional regulator complexes by binding to (or 'reading') acetyl-lysine marks on histone tails. The regulator complexes thus formed, control expression of sets of proteins which alter the cellular phenotype in specific ways. (BRD)-containing proteins are exciting targets for the development of novel small molecule therapeutics in the areas of cancer, inflammation and viral infection [1].


Targets of relevance to immunopharmacology are highlighted in blue

BRD1 (bromodomain containing 1) Show summary » More detailed page

BRD2 (bromodomain containing 2) Show summary » More detailed page

BRD3 (bromodomain containing 3) Show summary » More detailed page

BRD4 (bromodomain containing 4) Show summary » More detailed page

BRD7 (bromodomain containing 7) Show summary » More detailed page

BRD8 (bromodomain containing 8) Show summary » More detailed page

BRD9 (bromodomain containing 9) Show summary » More detailed page


Show »

How to cite this family page

Database page citation:

Bromodomain kinase (BRDK) family. Accessed on 15/12/2018. IUPHAR/BPS Guide to PHARMACOLOGY,

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2017) The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol. 174 Suppl 1: S272-S359.